论文部分内容阅读
血源性乙肝疫苗(P V)目前已广泛使用,并且证实了它的安全性、免疫原性及有效性。虽然如此,P V由于来源受限及价格昂贵和含有未知的致病物质,随着医学科学的发展,新出现的DNA重组乙肝疫苗(重组疫苗RV)对此已有很大的克服。为了解两组乙肝疫苗的效果,作者对两个幼儿园的儿童进行接种,分析结果如下: 材料与方法日本冲绳岛两个幼儿园0～5岁儿童,I组243名(男125、女119),平均年龄2.7岁,接受P V,剂量10μg;Ⅱ组118名(男56、女62),平均年龄2.9岁,接受RV、剂量5μg。两组均经皮
Blood-borne hepatitis B vaccine (P V) is now widely used and has demonstrated its safety, immunogenicity and efficacy. However, with the development of medical science, the newly emerged DNA recombinant hepatitis B vaccine (recombinant vaccine RV) has been greatly overcome due to its limited source and high cost and unknown pathogenic substances. To understand the effect of two hepatitis B vaccines, the authors vaccinated children in two kindergartens. The results were as follows: Materials and Methods Two kindergarten children aged 0-5 years in Okinawa, Japan, were enrolled in Group I (243, 125, 119) The mean age was 2.7 years. The patients received PV at a dosage of 10μg. The patients in group Ⅱ (118 men and 56%) with an average age of 2.9 years received RV in a dose of 5μg. Both groups were transdermally